Learning outcomes
By the end of this lesson you should be able to: describe the four stages of nociception and the peripheral and central sites at which analgesics act; distinguish the opioid receptors and the strong from the weak opioids, with their adverse effects and their management in overdose; explain the mechanism and limits of NSAIDs and paracetamol and the adverse-effect profiles that separate them; describe the WHO analgesic ladder and its application; and construct an adjuvant regimen for neuropathic and cancer-related pain.
Prerequisites
Lessons 1 to 6, and the pain module of the physiology course — nociceptors, the spinothalamic tract and the descending inhibitory pathways.
The big idea
Nociception has four stages — transduction at the nociceptor, transmission along the afferent fibre and the spinothalamic tract, modulation by the descending pathways, and perception in the cortex. Injury releases prostaglandins, bradykinin and cytokines that sensitise the nociceptors (transduction), so a drug that stops prostaglandin synthesis stops the sensitisation at its source, which is why an NSAID is more effective against inflammatory pain than against phantom or neuropathic pain. Opioids work centrally, on the mu receptors of the ascending inhibitory system and on the descending pain-control pathways, which is why a dose of morphine reaches pain of any cause but pays for it with respiratory depression and sedation. The distinction between inflammatory and neuropathic pain is the one that determines the whole regimen.
Opioid receptors and the opioid drugs
| Receptor | Effect | Agonist use |
|---|---|---|
| Mu (morphine) | Supraspinal analgesia, euphoria, respiratory depression, miosis, physical dependence, slowing of the gut | The principal therapeutic target of all strong opioids |
| Kappa | Spinal analgesia and miosis, with dysphoria and hallucinations, less respiratory depression | Partial contribution of the mixed agents; dynorphins |
| Delta | Spinal and supraspinal analgesia with a smaller respiratory effect | The endogenous enkephalins and experimental derivatives |
| Agent | Relative potency and duration | Particular use and adverse effects |
|---|---|---|
| Morphine | The reference strong opioid, 4 to 6 hours | Severe pain of any cause, acute pulmonary oedema, myocardial infarction; active metabolites accumulate in renal failure causing myoclonus and sedation |
| Fentanyl | About 100 times more potent, short duration when intravenous | Procedural sedation, anaesthetic adjunct, transdermal patches in chronic pain; chest wall rigidity at fast injection |
| Oxycodone | Oral strong opioid with good bioavailability | Step three of the WHO ladder and post-operative pain; the same sedation and constipation profile |
| Codeine and dihydrocodeine | Weak opioids requiring metabolism to morphine (codeine by CYP2D6) | Mild to moderate pain; poor metabolisers get no analgesia and ultrarapid metaboliser mothers risk neonatal toxicity |
| Tramadol | Weak mu agonism plus serotonin and noradrenaline reuptake inhibition | Moderate pain; seizures and serotonin syndrome at high dose or with interacting antidepressants |
| Methadone | Long half-life (days) with a complex kinetics | Opioid substitution in addiction, and specialist chronic pain; QT prolongation and accumulation deaths in inexperienced hands |
Watch outThe two opioid adverse effects that matter most separate themselves by tolerance. Respiratory depression and sedation are dose-related and the patient develops tolerance to them, but constipation never develops tolerance — it is a guaranteed effect that needs a laxative prescribed with the very first prescription, not added when the patient stops opening their bowels. Miosis, nausea and itch are the other early effects.
Opioid overdose produces the triad of coma, pinpoint pupils and respiratory depression, and the antidote is naloxone, a short-acting mu antagonist given in titrated doses to restore breathing without precipitating full withdrawal. Because naloxone's half-life is shorter than most opioids, a dependent patient or a long-acting overdose must be observed and infused, not discharged after a single response. Patient-controlled analgesia solves the pharmacological problem of titration: small intravenous boluses on demand, letting the patient keep the plasma concentration just above the point where pain beats sedation, with the risk of programmable error from programmer and pump alike.
Non-opioid analgesics
NSAIDs inhibit cyclo-oxygenase and so reduce prostaglandin synthesis — analgesia, antipyoresis and anti-inflammation from one mechanism — but the same prostaglandin inhibition produces their characteristic adverse effects: gastric and duodenal ulceration with bleeding, renal impairment from unopposed afferent vasoconstriction, bronchospasm in aspirin-sensitive asthma, fluid retention and hypertension, and platelet dysfunction that prolongs bleeding.
| Drug | Selectivity | Notes and adverse effects |
|---|---|---|
| Aspirin | Non-selective COX inhibitor, irreversible at low dose | Low dose for antiplatelet prophylaxis; at analgesic doses it can cause Reye's syndrome in children, tinnitus and salicylate toxicity |
| Ibuprofen, naproxen | Non-selective, short and longer acting | The commonest prescription NSAIDs; ulceration risk rises with dose, prior ulcer, concurrent corticosteroid, anticoagulant and age |
| Celecoxib | Selective COX-2 inhibitor | Less gastrointestinal ulceration and no antiplatelet effect, but cardiovascular thrombotic risk and the sulfonamide allergy caveat |
| Paracetamol | Central COX inhibition and endocannabinoid reuptake, with weak anti-inflammatory action | No gastric, renal or platelet effect at therapeutic doses, safe in asthma and in pregnancy; hepatic necrosis in overdose |
NoteThe triple whammy is the renal emergency of analgesia: an ACE inhibitor (efferent vasodilation) plus a diuretic (volume depletion) plus an NSAID (afferent vasoconstriction) drop the glomerular filtration suddenly, precipitating renal failure and hyperkalaemia. It happens most often in exactly the heart failure patient for whom all three drugs were separately appropriate, and the NSAID is the one that stops.
Paracetamol overdose is the commonest deliberate self-poisoning admission and one of the few pharmacological emergencies with a clean antidote. The toxic metabolite NAPQI accumulates when glutathione is exhausted and binds hepatic proteins, and N-acetylcysteine replenishes the glutamate for glutathione synthesis and substitutes directly for the depleted reserves. It is almost completely protective if given within eight hours of the ingestion, useful for a long time after, and the plasma level taken four hours post-overdose against the nomogram decides the level of certainty. Therapeutics: overdose, the first-line treatment is measurement and NAC — not a wait for symptoms.
Adjuvants and the WHO ladder
An adjuvant analgesic is not an analgesic at standard doses but treats a particular pain mechanism. The stepwise World Health Organization ladder organises the whole into three steps and is validated for cancer pain but generalises: at step one, a non-opioid with or without an adjuvant; at step two, a weak opioid; at step three, a strong opioid, with the non-opioid continued for its mechanism and the adjuvant continued for the biology of the pain.
| Step | Pain | Prescription | Notes |
|---|---|---|---|
| 1 | Mild | Paracetamol or an NSAID (plus adjuvant) | Regular dosing beats demand dosing for persistent pain |
| 2 | Moderate | Add codeine or tramadol to step one | Combination preparations hide dose escalation and slow therapeutic adjustment |
| 3 | Severe | Replace the weak opioid with morphine (or an equivalent) with paracetamol and adjuvant retained | Titrate by trough effect; breakthrough doses are extra immediate-release doses of a fraction of the total daily |
| Adjuvant | Mechanism | When used |
|---|---|---|
| Amitriptyline, nortriptyline, duloxetine | Serotonin and noradrenaline reuptake inhibition in the descending pain pathways | First-line for neuropathic pain: post-herpetic neuralgia, diabetic neuropathy |
| Gabapentin, pregabalin | Bind the alpha-2-delta subunit of the voltage-gated calcium channel, reducing excitatory transmitter release | Neuropathic pain; sedation and weight gain limit the dose |
| Dexamethasone | Reduces peritumoural inflammatory oedema | Metastatic bone pain, headache from raised intracranial pressure, spinal cord compression during definitive treatment |
| Lidocaine patch, capsaicin | Local sodium channel and vanilloid desensitization | Localised neuropathic and post-herpetic pain with few systemic effects |
| Baclofen, diazepam | Central muscle-relaxing actions | Muscle spasm in spasticity; sedation limits their utility |
Why is morphine used for the pain of acute myocardial infarction while NSAIDs are avoided?
Common mistakes
Watch outForgetting to prescribe a laxative with a strong opioid. Constipation is the one opioid effect to which no tolerance develops, so prophylaxis is part of the prescription rather than a response to the symptom.
Watch outDoubling a manufacturer's ceiling dose of a co-codamol combination to get a stronger opioid effect. Paracetamol overdose from unsuspected accumulation in combination products is the classic adverse drug event; prescribe the opioid and the paracetamol separately so each can be titrated safely.
Watch outTreating neuropathic pain with escalating NSAIDs. The sensitised nociceptor is not the mechanism in nerve injury; the evidence is for the antidepressants and gabapentinoids, and NSAIDs add only adverse effects.
Watch outGiving naloxone once and discharging. Naloxone is shorter acting than most opioids, so respiratory depression returns when it wears off; the dependent patient develops withdrawal while the overdose reasserts itself.
Check your understanding
Which opioid adverse effect does not develop tolerance, and what does that dictate?
How do NSAIDs and paracetamol differ in their adverse-effect profile?
A patient with diabetic neuropathy is on increasing doses of ibuprofen with no relief. What class of drug is indicated?
Multiple choice
Which opioid adverse effect does NOT develop tolerance with continued use?
Which is the antidote for opioid overdose?
Which is the mechanism of paracetamol toxicity in overdose?
Which group of drugs is first-line for neuropathic pain?
Which consequences follow from combining an ACE inhibitor, a diuretic and an NSAID?